30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Histogenics to Explore Strategic Alternatives for NeoCart Cartilage Treatment -

Histogenics plans to evaluate the range of potential strategic alternatives for its NeoCart® cell therapy following FDA's indication that an additional clinical trial would be required before acceptance of a Biologics License Application submission. Histogenics expects to suspend development of the tissue engineered implant and does not plan to submit a BLA at this time. (Histogenics Corporation, 12/21/18)